{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:21:48Z","timestamp":1791397308592,"version":"4.3.3"},"reference-count":246,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ymgme.2021.03.002","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T04:17:14Z","timestamp":1615522634000},"page":"8-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["The natural history of neurocognition in MPS disorders: A review"],"prefix":"10.1016","volume":"133","author":[{"given":"Elsa G.","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie B.","family":"Eisengart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2021.03.002_bb0005","series-title":"Quantitative Brain MRI Morphology in Patients With Severe and Attenuated Forms of Mucopolysacharidosis, Type I","author":"Kovac","year":"2020"},{"issue":"9","key":"10.1016\/j.ymgme.2021.03.002_bb0010","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1212\/01.wnl.0000269782.80107.fe","article-title":"Brain MRI in mucopolysaccharidosis: effect of aging and correlation with biochemical findings","volume":"69","author":"Vedolin","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3174\/ajnr.A2832","article-title":"Brain and spinal MR imaging findings in mucopolysaccharidoses: a review","volume":"34","author":"Zafeiriou","year":"2013","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ymgme.2017.09.006","article-title":"Quantitative neuroimaging in mucopolysaccharidoses clinical trials","volume":"122s","author":"Nestrasil","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2017.09.007","article-title":"Assessments of neurocognitive and behavioral function in the mucopolysaccharidoses","volume":"122s","author":"Shapiro","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2021.03.002_bb0030","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1542\/peds.2008-0999","article-title":"Multidisciplinary management of Hunter syndrome","volume":"124","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"Mucopolysaccharidosis I: management and treatment guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"issue":"457","key":"10.1016\/j.ymgme.2021.03.002_bb0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1651-2227.2008.00651.x","article-title":"Methods for assessing neurodevelopment in lysosomal storage diseases and related disorders: a multidisciplinary perspective","volume":"97","author":"Martin","year":"2008","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0045","first-page":"129","article-title":"Methods of neurodevelopmental assessment in children with neurodegenerative disease: Sanfilippo syndrome","volume":"13","author":"Delaney","year":"2014","journal-title":"JIMD Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0050","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1037\/0003-066X.56.2.128","article-title":"Psychological testing and psychological assessment: a review of evidence and issues","volume":"56","author":"Meyer","year":"2001","journal-title":"Am. Psychol."},{"issue":"1-2","key":"10.1016\/j.ymgme.2021.03.002_bb0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ymgme.2020.08.007","article-title":"Therapy development for the mucopolysaccharidoses: updated consensus recommendations for neuropsychological endpoints","volume":"131","author":"van der Lee","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0060","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2017.05.005","article-title":"Cognitive and adaptive measurement endpoints for clinical trials in mucopolysaccharidoses types I, II, and III: A review of the literature","volume":"121","author":"Janzen","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0065","article-title":"Epidemiology of Mucopolysaccharidoses Update","volume":"11","author":"\u00c7elik","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ymgme.2021.03.002_bb0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymgme.2017.10.007","article-title":"Treatment of brain disease in the mucopolysaccharidoses","volume":"122s","author":"Scarpa","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"13","key":"10.1016\/j.ymgme.2021.03.002_bb0075","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","article-title":"Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study","volume":"125","author":"Aldenhoven","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ymgme.2021.03.002_bb0080","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40265-019-01147-4","article-title":"Therapeutic options for mucopolysaccharidoses: current and emerging treatments","volume":"79","author":"Sawamoto","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0085","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymgme.2017.05.004","article-title":"Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: Results of a consensus procedure","volume":"121","author":"van der Lee","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0090","series-title":"Advances in Child Neuropsychology","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-1-4612-2608-6_4","article-title":"Dementia in childhood: issues in neuropsychological assessment with application to the natural history and treatment of degenerative storage diseases","author":"Shapiro","year":"1994"},{"key":"10.1016\/j.ymgme.2021.03.002_bb0095","series-title":"Pediatric Neuropsychology: Research, Theory and Practice","first-page":"171","article-title":"Metabolic and neurodegenerative disorders of childhood","author":"Shapiro","year":"2000"},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13023-018-0817-3","article-title":"Beneath the floor: re-analysis of neurodevelopmental outcomes in untreated Hurler syndrome","volume":"13","author":"Shapiro","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0105","series-title":"Technical Manual, Bayley Scale of Infant and Toddler Development","author":"Bayley","year":"2006"},{"issue":"8","key":"10.1016\/j.ymgme.2021.03.002_bb0110","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3390\/cells9081838","article-title":"Mucopolysaccharidosis Type I: a review of the natural history and molecular pathology","volume":"9","author":"Hampe","year":"2020","journal-title":"Cells"},{"issue":"1-2","key":"10.1016\/j.ymgme.2021.03.002_bb0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymgme.2015.06.002","article-title":"Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment","volume":"116","author":"Shapiro","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"8249","key":"10.1016\/j.ymgme.2021.03.002_bb0120","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(81)91046-1","article-title":"Reversal of clinical features of Hurler\u2019s disease and biochemical improvement after treatment by bone-marrow transplantation","volume":"2","author":"Hobbs","year":"1981","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0125","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ajmg.1320460222","article-title":"Long-term outcome of Hurler syndrome following bone marrow transplantation","volume":"46","author":"Whitley","year":"1993","journal-title":"Am. J. Med. Genet."},{"issue":"11","key":"10.1016\/j.ymgme.2021.03.002_bb0130","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood.V87.11.4894.bloodjournal87114894","article-title":"Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome","volume":"87","author":"Peters","year":"1996","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ymgme.2021.03.002_bb0135","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood.V91.7.2601","article-title":"Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group","volume":"91","author":"Peters","year":"1998","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ymgme.2021.03.002_bb0140","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.24246","article-title":"Early treatment is associated with improved cognition in Hurler syndrome","volume":"76","author":"Poe","year":"2014","journal-title":"Ann. Neurol."},{"issue":"19","key":"10.1016\/j.ymgme.2021.03.002_bb0145","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1056\/NEJMoa032613","article-title":"Cord-blood transplants from unrelated donors in patients with Hurler\u2019s syndrome","volume":"350","author":"Staba","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2021.03.002_bb0150","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/sj.bmt.1705934","article-title":"Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome","volume":"41","author":"Tolar","year":"2008","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0155","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jpeds.2008.07.004","article-title":"Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients","volume":"154","author":"Wynn","year":"2009","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jpeds.2012.07.052","article-title":"Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome","volume":"162","author":"Eisengart","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0165","first-page":"64","article-title":"Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome","volume":"13","author":"Eisengart","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"11","key":"10.1016\/j.ymgme.2021.03.002_bb0170","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/gim.2018.29","article-title":"Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison","volume":"20","author":"Eisengart","year":"2018","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb0175","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ymgme.2016.01.011","article-title":"Enzyme replacement therapy prior to haematopoietic stem cell transplantation in Mucopolysaccharidosis Type I: 10 year combined experience of 2 centres","volume":"117","author":"Ghosh","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0180","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10545-016-0006-2","article-title":"Mortality after hematopoietic stem cell transplantation for severe mucopolysaccharidosis type I: the 30-year University of Minnesota experience","volume":"40","author":"Rodgers","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0185","first-page":"91","article-title":"Outcome After Cord Blood Transplantation Using Busulfan Pharmacokinetics-Targeted Myeloablative Conditioning for Hurler Syndrome","volume":"27.1","author":"Lum","year":"2021","journal-title":"Biol. Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0190","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1590\/S1415-47572014000100006","article-title":"Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network","volume":"37","author":"Dornelles","year":"2014","journal-title":"Genet. Mol. Biol."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0195","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.GIM.0000078027.83236.49","article-title":"Can mucopolysaccharidosis type I disease severity be predicted based on a patient\u2019s genotype? A comprehensive review of the literature","volume":"5","author":"Terlato","year":"2003","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0200","series-title":"JIMD Reports","first-page":"95","article-title":"Long-term cognitive and functional outcomes in children with mucopolysaccharidosis (MPS)-IH (hurler syndrome) treated with hematopoietic cell transplantation","volume":"vol. 29","author":"Kunin-Batson","year":"2015"},{"key":"10.1016\/j.ymgme.2021.03.002_bb0205","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jpeds.2016.11.036","article-title":"Mucopolysaccharidosis type I newborn screening: best practices for diagnosis and management","volume":"182","author":"Clarke","year":"2017","journal-title":"J. Pediatr."},{"issue":"11","key":"10.1016\/j.ymgme.2021.03.002_bb0210","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/s41436-019-0522-1","article-title":"Intrathecal enzyme replacement for Hurler syndrome: biomarker association with neurocognitive outcomes","volume":"21","author":"Eisengart","year":"2019","journal-title":"Genet. Med."},{"issue":"1-2","key":"10.1016\/j.ymgme.2021.03.002_bb0215","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ymgme.2012.07.016","article-title":"An exploratory study of brain function and structure in mucopolysaccharidosis type I: long term observations following hematopoietic cell transplantation (HCT)","volume":"107","author":"Shapiro","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"20","key":"10.1016\/j.ymgme.2021.03.002_bb0220","doi-asserted-by":"crossref","first-page":"e2321","DOI":"10.1212\/WNL.0000000000007496","article-title":"Attention and corpus callosum volumes in individuals with mucopolysaccharidosis type I","volume":"92","author":"King","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0225","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jpeds.2009.07.005","article-title":"Guidelines for the management of mucopolysaccharidosis type I","volume":"155","author":"Martins","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0230","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13023-015-0344-4","article-title":"Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships","volume":"10","author":"Al-Sannaa","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0235","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12881-016-0284-4","article-title":"12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment","volume":"17","author":"Gabrielli","year":"2016","journal-title":"BMC Med. Genet."},{"issue":"6","key":"10.1016\/j.ymgme.2021.03.002_bb0240","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pediatrneurol.2012.08.010","article-title":"Enzyme replacement therapy in an attenuated case of mucopolysaccharidosis type I (Scheie syndrome): a 6.5-year detailed follow-up","volume":"47","author":"Jurecka","year":"2012","journal-title":"Pediatr. Neurol."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0245","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ymgme.2009.12.019","article-title":"Cognitive and neuroradiological improvement in three patients with attenuated MPS I treated by laronidase","volume":"100","author":"Valayannopoulos","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0250","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ymgme.2009.07.015","article-title":"Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II","volume":"98","author":"Wang","year":"2009","journal-title":"Mol. Genet. Metab."},{"issue":"7","key":"10.1016\/j.ymgme.2021.03.002_bb0255","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1651-2227.2005.tb02004.x","article-title":"Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I","volume":"94","author":"Vijay","year":"2005","journal-title":"Acta Paediatr."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb0260","doi-asserted-by":"crossref","DOI":"10.4238\/gmr16032602","article-title":"Clinical features of Mexican patients with Mucopolysaccharidosis type I","volume":"16","author":"Alonzo-Rojo","year":"2017","journal-title":"Genet. Mol. Res."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0265","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ymgme.2013.11.014","article-title":"Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the \u03b1-L-iduronidase gene in Hurler-Scheie syndrome","volume":"111","author":"Ahmed","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0270","first-page":"27","article-title":"Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI","volume":"7","author":"Ahmed","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb0275","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ajmg.a.20515","article-title":"Correlation between cerebral MRI abnormalities and mental retardation in patients with mucopolysaccharidoses","volume":"125a","author":"Gabrielli","year":"2004","journal-title":"Am. J. Med. Genet. A"},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0280","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.ymgme.2021.03.002_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184065","article-title":"Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: a systematic review and meta-analysis","volume":"12","author":"Dornelles","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0290","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ymgme.2007.01.011","article-title":"The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I","volume":"91","author":"Pastores","year":"2007","journal-title":"Mol. Genet. Metab."},{"issue":"10","key":"10.1016\/j.ymgme.2021.03.002_bb0295","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/gim.2014.25","article-title":"The natural history of MPS I: global perspectives from the MPS I Registry","volume":"16","author":"Beck","year":"2014","journal-title":"Genet. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0300","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10545-010-9113-7","article-title":"Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I","volume":"33","author":"Thomas","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0305","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ymgme.2019.11.007","article-title":"Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis type I, a randomized, open-label, controlled pilot study","volume":"129","author":"Chen","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb0310","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajmg.a.38073","article-title":"Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I","volume":"173","author":"Nestrasil","year":"2017","journal-title":"Am. J. Med. Genet. A"},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0315","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1542\/peds.2006-2156","article-title":"Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"120","author":"Wraith","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2021.03.002_bb0320","first-page":"100484","article-title":"A longitudinal study of neurocognition and behavior in patients with Hurler-Scheie syndrome heterozygous for the L238Q mutation","volume":"20","author":"Ahmed","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0325","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.ymgme.2019.11.118","article-title":"Evidence of problems with \u201cprocessing efficiency\u201d in attenuated mucopolysaccharidosis type I","volume":"129","author":"Eisengart","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0330","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","article-title":"Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS)","volume":"32","author":"Jones","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2021.03.002_bb0335","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10545-017-0075-x","article-title":"Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS)","volume":"40","author":"Burton","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0340","series-title":"Lysosomal Storage Disorders","first-page":"407","article-title":"Mucopolysaccharidosis II (Hunter Syndrome)","author":"Clarke","year":"2007"},{"key":"10.1016\/j.ymgme.2021.03.002_bb0345","first-page":"99","article-title":"Enzyme replacement therapy in mucopolysaccharidosis II patients under 1 year of age","volume":"14","author":"Lampe","year":"2014","journal-title":"JIMD Rep."},{"issue":"6","key":"10.1016\/j.ymgme.2021.03.002_bb0350","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/jmg.19.6.408","article-title":"A clinical and genetic study of Hunter\u2019s syndrome. 2. Differences between the mild and severe forms","volume":"19","author":"Young","year":"1982","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0355","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jpeds.2011.03.019","article-title":"Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II","volume":"159","author":"Holt","year":"2011","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0360","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1542\/peds.2007-1350","article-title":"Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome)","volume":"121","author":"Martin","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2021.03.002_bb0365","first-page":"100630","article-title":"Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter syndrome): Contribution of genotype to cognitive developmental course","volume":"24","author":"Seo","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"5","key":"10.1016\/j.ymgme.2021.03.002_bb0370","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","article-title":"Natural progression of neurological disease in mucopolysaccharidosis type II","volume":"127","author":"Holt","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2021.03.002_bb0375","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.ymgme.2015.12.444","article-title":"Attenuated mucopolysaccharidosis II; parental beliefs about the impact of disease on the quality of life of their children","volume":"117","author":"Soni-Jaiswal","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0380","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2019.07.016","article-title":"Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England","volume":"129","author":"Broomfield","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0385","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10545-008-0878-x","article-title":"Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed","volume":"31","author":"Al Sawaf","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"455","key":"10.1016\/j.ymgme.2021.03.002_bb0390","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1651-2227.2007.00212.x","article-title":"A clinical study of 77 patients with mucopolysaccharidosis type II","volume":"96","author":"Schwartz","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0395","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13023-014-0129-1","article-title":"Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years","volume":"9","author":"Tomanin","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0400","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1111\/j.1651-2227.2011.02385.x","article-title":"Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up","volume":"101","author":"Tylki-Szymanska","year":"2012","journal-title":"Acta Paediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0405","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ymgme.2014.12.299","article-title":"Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II","volume":"114","author":"Yund","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb0410","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2016.05.003","article-title":"Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase","volume":"118","author":"Kosuga","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"439","key":"10.1016\/j.ymgme.2021.03.002_bb0415","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1651-2227.2002.tb03116.x","article-title":"Mucopolysaccharidosis type II--genotype\/phenotype aspects","volume":"91","author":"Froissart","year":"2002","journal-title":"Acta Paediatr. Suppl."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb0420","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol. Genet. Metab."},{"issue":"10","key":"10.1016\/j.ymgme.2021.03.002_bb0425","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/dmcn.13467","article-title":"Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype","volume":"59","author":"Vollebregt","year":"2017","journal-title":"Dev. Med. Child Neurol."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb0430","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/adc.79.3.237","article-title":"Mutation analysis in 57 unrelated patients with MPS II (Hunter\u2019s disease)","volume":"79","author":"Vafiadaki","year":"1998","journal-title":"Arch. Dis. Child."},{"issue":"11","key":"10.1016\/j.ymgme.2021.03.002_bb0435","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/hmg\/2.11.1871","article-title":"Iduronate-2-sulfatase gene mutations in 16 patients with mucopolysaccharidosis type II (Hunter syndrome)","volume":"2","author":"Bunge","year":"1993","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.ymgme.2021.03.002_bb0440","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1005432600871","article-title":"Hunter disease in the Spanish population: molecular analysis in 31 families","volume":"21","author":"Gort","year":"1998","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0445","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1023\/A:1005363414792","article-title":"Mutation analysis in the iduronate-2-sulphatase gene in 43 Japanese patients with mucopolysaccharidosis type II (Hunter disease)","volume":"21","author":"Isogai","year":"1998","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0450","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/humu.1169","article-title":"Molecular analysis of 40 Italian patients with mucopolysaccharidosis type II: new mutations in the iduronate-2-sulfatase (IDS) gene","volume":"18","author":"Filocamo","year":"2001","journal-title":"Hum. Mutat."},{"issue":"8","key":"10.1016\/j.ymgme.2021.03.002_bb0455","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2021.03.002_bb0460","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/jmg.19.6.401","article-title":"A clinical and genetic study of Hunter\u2019s syndrome. 1. Heterogeneity","volume":"19","author":"Young","year":"1982","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0465","first-page":"103","article-title":"Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment","volume":"5","author":"Hendriksz","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"7","key":"10.1016\/j.ymgme.2021.03.002_bb0470","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3174\/ajnr.A2032","article-title":"Correlation of automated volumetric analysis of brain MR imaging with cognitive impairment in a natural history study of mucopolysaccharidosis II","volume":"31","author":"Fan","year":"2010","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0475","doi-asserted-by":"crossref","first-page":"63","DOI":"10.6000\/2292-2598.2016.04.01.8","article-title":"Mucopolysaccharidosis II, IV-A and VI: first Colombian neuropsychological characterization","volume":"4","author":"Ib\u00e1\u00f1ez","year":"2016","journal-title":"J. Intellect. Disabil.-Diagn. Treat."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0480","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","article-title":"The natural history of the severe form of Hunter\u2019s syndrome: a study based on 52 cases","volume":"25","author":"Young","year":"1983","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0485","first-page":"S103","article-title":"Neurodevelopmental status and adaptive behavior of pediatric patients with Hunter syndrome: A longitudinal observational study","volume":"126","author":"Muenzer","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"10","key":"10.1016\/j.ymgme.2021.03.002_bb0490","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol. Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.ymgme.2021.03.002_bb0495","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jpeds.2008.11.041","article-title":"Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years","volume":"154","author":"Guffon","year":"2009","journal-title":"J. Pediatr."},{"issue":"5","key":"10.1016\/j.ymgme.2021.03.002_bb0500","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1023\/A:1005525931994","article-title":"Long-term follow-up following bone marrow transplantation for Hunter disease","volume":"22","author":"Vellodi","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0505","first-page":"81","article-title":"Effectiveness of early hematopoietic stem cell transplantation in preventing neurocognitive decline in mucopolysaccharidosis type II: a case series","volume":"41","author":"Selvanathan","year":"2018","journal-title":"JIMD Rep."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb0510","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","article-title":"Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan","volume":"107","author":"Tanaka","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb0515","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ymgme.2012.12.010","article-title":"Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: comparison in two siblings","volume":"108","author":"Tajima","year":"2013","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2021.03.002_bb0520","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10545-014-9686-7","article-title":"Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series","volume":"37","author":"Lampe","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0525","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13023-017-0635-z","article-title":"Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry","volume":"12","author":"Muenzer","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"issue":"11","key":"10.1016\/j.ymgme.2021.03.002_bb0530","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/adc.57.11.828","article-title":"Mild form of Hunter\u2019s syndrome: clinical delineation based on 31 cases","volume":"57","author":"Young","year":"1982","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0535","first-page":"32","article-title":"A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II","volume":"7","author":"Shapiro","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb0540","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s10897-013-9665-4","article-title":"MPS II: adaptive behavior of patients and impact on the family system","volume":"23","author":"Needham","year":"2014","journal-title":"J. Genet. Couns."},{"issue":"8","key":"10.1016\/j.ymgme.2021.03.002_bb0545","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10038-005-0266-4","article-title":"Mutational and structural analysis of Japanese patients with mucopolysaccharidosis type II","volume":"50","author":"Kato","year":"2005","journal-title":"J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0550","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1111\/j.1651-2227.2011.02522.x","article-title":"Restricted joint range of motion in patients with MPS II: correlation with height, age and functional status","volume":"101","author":"Marucha","year":"2012","journal-title":"Acta Paediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0555","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1442-200X.2008.02652.x","article-title":"Psychological status of patients with mucopolysaccharidosis type II and their parents","volume":"51","author":"Kuratsubo","year":"2009","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0560","first-page":"132","article-title":"A longitudinal report of neurocognitive abnormalities and their impact on Quality of Life in non-neuronopathic MPS II","author":"Yund","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2021.03.002_bb0565","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/02643294.2017.1401530","article-title":"Cognitive and behaviour profiles of children with mucopolysaccharidosis Type II","volume":"34","author":"Crowe","year":"2017","journal-title":"Cogn. Neuropsychol."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0570","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1750-1172-6-43","article-title":"Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome)","volume":"6","author":"Valstar","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0575","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13023-019-1150-1","article-title":"Analysis of the caregiver burden associated with Sanfilippo syndrome type B: panel recommendations based on qualitative and quantitative data","volume":"14","author":"Shapiro","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0580","first-page":"1","article-title":"Parent experiences of Sanfilippo syndrome impact and unmet treatment needs: a qualitative assessment","author":"Porter","year":"2020","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0585","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13023-018-0796-4","article-title":"Epidemiology of Sanfilippo syndrome: results of a systematic literature review","volume":"13","author":"Zelei","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0590","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0022-3476(63)80279-6","article-title":"Mental retardation associated with acid mucopolysacchariduria (heparitin sulfate type)","volume":"63","author":"Sanfilippo","year":"1963","journal-title":"J. Pediatr."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0595","first-page":"174","article-title":"The Sanfilippo syndrome: clinical, biochemical, radiological, haematological and pathological features of nine cases","volume":"8","author":"Danks","year":"1972","journal-title":"Aust. Paediatr. J."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0600","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1399-0004.1981.tb01821.x","article-title":"Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C)","volume":"20","author":"van de Kamp","year":"1981","journal-title":"Clin. Genet."},{"issue":"Pt 3","key":"10.1016\/j.ymgme.2021.03.002_bb0605","first-page":"185","article-title":"Developmental and degenerative patterns associated with cognitive, behavioural and motor difficulties in the Sanfilippo syndrome: an epidemiological study","volume":"27","author":"Nidiffer","year":"1983","journal-title":"J. Ment. Defic. Res."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb0610","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/adc.69.3.403","article-title":"Management of mucopolysaccharidosis type III","volume":"69","author":"Cleary","year":"1993","journal-title":"Arch. Dis. Child."},{"issue":"5","key":"10.1016\/j.ymgme.2021.03.002_bb0615","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-2007-973503","article-title":"Clinical and neuroradiological follow-up in mucopolysaccharidosis type III (Sanfilippo syndrome)","volume":"30","author":"Barone","year":"1999","journal-title":"Neuropediatrics"},{"issue":"5","key":"10.1016\/j.ymgme.2021.03.002_bb0620","doi-asserted-by":"crossref","first-page":"e1255","DOI":"10.1542\/peds.2007-0282","article-title":"Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A)","volume":"120","author":"Meyer","year":"2007","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0625","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1023\/A:1005362826552","article-title":"Identification of a common mutation (R245H) in Sanfilippo A patients from The Netherlands","volume":"21","author":"Weber","year":"1998","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0630","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/(SICI)1098-1004(1998)11:4<313::AID-HUMU9>3.0.CO;2-P","article-title":"Identification of molecular defects in Italian Sanfilippo A patients including 13 novel mutations","volume":"11","author":"Di Natale","year":"1998","journal-title":"Hum. Mutat."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2021.03.002_bb0635","first-page":"133","article-title":"Mucopolysaccharidosis III (Sanfilippo Syndrome)- disease presentation and experimental therapies","volume":"12","author":"Gilkes","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"issue":"5","key":"10.1016\/j.ymgme.2021.03.002_bb0640","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/humu.20738","article-title":"The mutation p.Ser298Pro in the sulphamidase gene (SGSH) is associated with a slowly progressive clinical phenotype in mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)","volume":"29","author":"Meyer","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0645","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jpeds.2015.11.079","article-title":"A prospective natural history study of mucopolysaccharidosis type IIIA","volume":"170","author":"Shapiro","year":"2016","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0650","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13023-019-1232-0","article-title":"The attenuated end of the phenotypic spectrum in MPS III: from late-onset stable cognitive impairment to a non-neuronopathic phenotype","volume":"14","author":"Nijmeijer","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0655","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1034\/j.1399-0004.2003.00053.x","article-title":"Analysis of Sanfilippo A gene mutations in a large pedigree","volume":"63","author":"Di Natale","year":"2003","journal-title":"Clin. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0660","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ajmg.a.33779","article-title":"Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece","volume":"155a","author":"H\u00e9ron","year":"2011","journal-title":"Am. J. Med. Genet. A"},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0665","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/humu.1189","article-title":"Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications","volume":"18","author":"Yogalingam","year":"2001","journal-title":"Hum. Mutat."},{"issue":"5","key":"10.1016\/j.ymgme.2021.03.002_bb0670","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1399-0004.1976.tb00049.x","article-title":"Clinical variability in Sanfilippo B disease: a report on six patients in two related sibships","volume":"10","author":"van de Kamp","year":"1976","journal-title":"Clin. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb0675","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ymgme.2016.08.002","article-title":"A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design","volume":"119","author":"Truxal","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0680","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jpeds.2018.01.044","article-title":"Observational prospective natural history of patients with Sanfilippo syndrome type B","volume":"197","author":"Whitley","year":"2018","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0685","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10545-008-0838-5","article-title":"Sanfilippo syndrome: a mini-review","volume":"31","author":"Valstar","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0690","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/jmg.36.1.28","article-title":"Mucopolysaccharidosis type IIIB (Sanfilippo B): identification of 18 novel alpha-N-acetylglucosaminidase gene mutations","volume":"36","author":"Bunge","year":"1999","journal-title":"J. Med. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2021.03.002_bb0695","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10545-005-0093-y","article-title":"Molecular defects in Sanfilippo syndrome type B (mucopolysaccharidosis IIIB)","volume":"28","author":"Beesley","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0700","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.ejhg.5200242","article-title":"Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes","volume":"7","author":"Weber","year":"1999","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0705","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ajmg.1320280118","article-title":"Follow-up on seven adult patients with mild Sanfilippo B-disease","volume":"28","author":"van Schrojenstein-de Valk","year":"1987","journal-title":"Am. J. Med. Genet."},{"issue":"6","key":"10.1016\/j.ymgme.2021.03.002_bb0710","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10545-010-9199-y","article-title":"Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype","volume":"33","author":"Valstar","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb0715","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ajmg.c.30142","article-title":"Is Sanfilippo type B in your mind when you see adults with mental retardation and behavioral problems?","volume":"145c","author":"Moog","year":"2007","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"issue":"9","key":"10.1016\/j.ymgme.2021.03.002_bb0720","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/ajmg.a.40351","article-title":"Mucopolysaccharidosis III in Taiwan: natural history, clinical and molecular characteristics of 28 patients diagnosed during a 21-year period","volume":"176","author":"Lin","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"issue":"9","key":"10.1016\/j.ymgme.2021.03.002_bb0725","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s100380200070","article-title":"Molecular analysis of the alpha-N-acetylglucosaminidase gene in seven Japanese patients from six unrelated families with mucopolysaccharidosis IIIB (Sanfilippo type B), including two novel mutations","volume":"47","author":"Tanaka","year":"2002","journal-title":"J. Hum. Genet."},{"issue":"7","key":"10.1016\/j.ymgme.2021.03.002_bb0730","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10038-005-0258-4","article-title":"Sanfilippo type B syndrome: five patients with an R565P homozygous mutation in the alpha-N-acetylglucosaminidase gene from the Okinawa islands in Japan","volume":"50","author":"Chinen","year":"2005","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0735","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cca.2013.01.009","article-title":"Mucopolysaccharidosis type IIIB mutations in Chinese patients: identification of two novel NAGLU mutations and analysis of two cases involving prenatal diagnosis","volume":"419","author":"Tang","year":"2013","journal-title":"Clin. Chim. Acta"},{"issue":"8","key":"10.1016\/j.ymgme.2021.03.002_bb0740","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1651-2227.2010.01800.x","article-title":"Mucopolysaccharidosis type III (Sanfilippo disease) in Sweden: clinical presentation of 22 children diagnosed during a 30-year period","volume":"99","author":"Malm","year":"2010","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0745","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/1750-1172-8-189","article-title":"Natural history of Sanfilippo syndrome in Spain","volume":"8","author":"Delgadillo","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb0750","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10545-013-9661-8","article-title":"Natural history of Sanfilippo syndrome type A","volume":"37","author":"Buhrman","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0755","series-title":"13th International MPS Symposium","article-title":"Are language and motor skills in Sanfilippo syndrome good indicators of disease progression?","author":"Shapiro","year":"2014"},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0760","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ymgme.2017.11.014","article-title":"Observing the advanced disease course in mucopolysaccharidosis, type IIIA; a case series","volume":"123","author":"Shapiro","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0765","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1016\/j.ymgme.2018.12.396","article-title":"Design, baseline characteristics, and 18-24 months follow-up from the MPS IIIA natural history study","volume":"126","author":"Wijburg","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0770","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1016\/j.ymgme.2018.12.351","article-title":"Natural history data for young subjects with Sanfilippo syndrome type B (MPS IIIB)","volume":"126","author":"Villarreal","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2021.03.002_bb0775","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/BF01800232","article-title":"Bone marrow transplantation for Sanfilippo disease type B","volume":"15","author":"Vellodi","year":"1992","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0780","first-page":"S176","article-title":"Poor cognitive outcome of eleven children with Sanfilippo syndrome after bone marrow transplantation and successful engraftment","volume":"15","author":"Klein","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0785","first-page":"100578","article-title":"Hematopoietic stem cell transplantation in mucopolysaccharidosis type IIIA: A case description and comparison with a genotype-matched control group","volume":"23","author":"K\u00f6hn","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0790","first-page":"63","article-title":"Early umbilical cord blood-derived stem cell transplantation does not prevent neurological deterioration in mucopolysaccharidosis type III","volume":"18","author":"Welling","year":"2015","journal-title":"JIMD Rep."},{"issue":"7","key":"10.1016\/j.ymgme.2021.03.002_bb0795","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1005526628598","article-title":"Bone marrow transplantation in mucopolysaccharidosis type IIIA: a comparison of an early treated patient with his untreated sibling","volume":"22","author":"Sivakumur","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"issue":"7","key":"10.1016\/j.ymgme.2021.03.002_bb0800","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.ejhg.5201623","article-title":"Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses","volume":"14","author":"Piotrowska","year":"2006","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0805","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.22643","article-title":"Genistein in Sanfilippo disease: a randomized controlled crossover trial","volume":"71","author":"de Ruijter","year":"2012","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0810","first-page":"S59","article-title":"High dose genistein aglycone in Sanfilippo syndrome: results of a randomized, double-blinded, placebo controlled clinical trial","volume":"126","author":"Ghosh","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0815","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ymgme.2018.10.006","article-title":"Intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A: A phase IIb randomized trial","volume":"126","author":"Wijburg","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"9","key":"10.1016\/j.ymgme.2021.03.002_bb0820","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0825","series-title":"Transpher A, A Multicenter, Single-Dose, Phase 1\/2 Clinical Trial of ABO-102, an Intravenous AAV9-Based Gene Therapy for Sanfilippo Syndrome Type A (Mucopolysaccharidosis IIIA)(4898)","author":"Flanigan","year":"2020"},{"key":"10.1016\/j.ymgme.2021.03.002_bb0830","series-title":"Safety, Tolerability, and Preliminary Evidence of Biopotency in Transpher B, a Multicenter, Singledose, Phase 1\/2 Clinical Trial of ABO-101 Gene Therapy for Sanfilippo Syndrome Type B (Mucopolysaccharidosis IIIB)(5175)","author":"McBride","year":"2020"},{"key":"10.1016\/j.ymgme.2021.03.002_bb0835","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.ymgme.2017.12.270","article-title":"ICV-administered BMN 250 (NAGLU-IGF2) is well tolerated and reduces heparan sulfate accumulation in the CNS of subjects with Sanfilippo syndrome type B (MPS IIIB)","volume":"123","author":"Muschol","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2021.03.002_bb0840","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/humu.20986","article-title":"Sanfilippo syndrome type C: mutation spectrum in the heparan sulfate acetyl-CoA: alpha-glucosaminide N-acetyltransferase (HGSNAT) gene","volume":"30","author":"Feldhammer","year":"2009","journal-title":"Hum. Mutat."},{"issue":"10","key":"10.1016\/j.ymgme.2021.03.002_bb0845","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007434","article-title":"Protein misfolding as an underlying molecular defect in mucopolysaccharidosis III type C","volume":"4","author":"Feldhammer","year":"2009","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0850","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2007.09.011","article-title":"Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands","volume":"93","author":"Ruijter","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0855","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1399-0004.1988.tb02846.x","article-title":"Mucopolysaccharidosis type IIIC (Sanfilippo): early clinical presentation in a large Turkish pedigree","volume":"34","author":"Sewell","year":"1988","journal-title":"Clin. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0860","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF00441361","article-title":"Sanfilippo type C disease: clinical findings in four patients with a new variant of mucopolysaccharidosis III","volume":"130","author":"Bartsocas","year":"1979","journal-title":"Eur. J. Pediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0865","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1651-2227.1985.tb10936.x","article-title":"Sanfilippo type C syndrome in two sisters","volume":"74","author":"Uvebrant","year":"1985","journal-title":"Acta Paediatr. Scand."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0870","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1055\/s-2008-1071272","article-title":"Sanfilippo disease, type C: three cases in the same family","volume":"20","author":"Turki","year":"1989","journal-title":"Neuropediatrics"},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0875","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0887-8994(96)00083-5","article-title":"Sanfilippo syndrome type C: a clinicopathological autopsy study of a long-term survivor","volume":"14","author":"Kurihara","year":"1996","journal-title":"Pediatr. Neurol."},{"issue":"8","key":"10.1016\/j.ymgme.2021.03.002_bb0880","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1007\/s00415-011-5977-1","article-title":"Co-morbidity of Sanfilippo syndrome type C and D-2-hydroxyglutaric aciduria","volume":"258","author":"Ali Pervaiz","year":"2011","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.ymgme.2021.03.002_bb0885","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/humu.9488","article-title":"Mutational analysis of the HGSNAT gene in Italian patients with mucopolysaccharidosis IIIC (Sanfilippo C syndrome). Mutation in brief #959. Online","volume":"28","author":"Fedele","year":"2007","journal-title":"Hum. Mutat."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0890","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF00441662","article-title":"Clinical heterogeneity in Sanfilippo disease (mucopolysaccharidosis III) type D: presentation of two new cases","volume":"140","author":"Coppa","year":"1983","journal-title":"Eur. J. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0895","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/BF00441147","article-title":"Sanfilippo type D disease: clinical findings in two patients with a new variant of mucopolysaccharidosis III","volume":"138","author":"Gatti","year":"1982","journal-title":"Eur. J. Pediatr."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0900","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/088307389400900415","article-title":"Sanfilippo type D presenting with acquired language disorder but without features of mucopolysaccharidosis","volume":"9","author":"Ozand","year":"1994","journal-title":"J. Child Neurol."},{"issue":"10","key":"10.1016\/j.ymgme.2021.03.002_bb0905","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/00005072-199710000-00010","article-title":"Human mucopolysaccharidosis IIID: clinical, biochemical, morphological and immunohistochemical characteristics","volume":"56","author":"Jones","year":"1997","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0910","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0022-3476(87)80171-3","article-title":"Sanfilippo syndrome type D","volume":"110","author":"Kaplan","year":"1987","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb0915","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/jmg.40.3.192","article-title":"Sanfilippo syndrome type D: identification of the first mutation in the N-acetylglucosamine-6-sulphatase gene","volume":"40","author":"Beesley","year":"2003","journal-title":"J. Med. Genet."},{"issue":"6","key":"10.1016\/j.ymgme.2021.03.002_bb0920","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/jmg.28.6.402","article-title":"Sanfilippo syndrome type D in two adolescent sisters","volume":"28","author":"Siciliano","year":"1991","journal-title":"J. Med. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2021.03.002_bb0925","first-page":"E1348","article-title":"Mucopolysaccharidosis type IIID: 12 new patients and 15 novel mutations","volume":"31","author":"Valstar","year":"2010","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0930","first-page":"45","article-title":"Current and emerging management options for patients with Morquio A syndrome","volume":"9","author":"Algahim","year":"2013","journal-title":"Ther. Clin. Risk Manag."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0935","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10545-007-0529-7","article-title":"International Morquio A Registry: clinical manifestation and natural course of Morquio A disease","volume":"30","author":"Monta\u00f1o","year":"2007","journal-title":"J. Inherited Metabolic Dis."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0940","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0929-693X(14)72257-2","article-title":"Natural history of Morquio A disease","volume":"21","author":"Baujat","year":"2014","journal-title":"Arch. Pediatr."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0945","series-title":"Lysosomal Storage Disorders","first-page":"433","article-title":"Mucopolysaccharidosis IV (Morquio syndrome)","author":"Tomatsu","year":"2007"},{"key":"10.1016\/j.ymgme.2021.03.002_bb0950","doi-asserted-by":"crossref","DOI":"10.1177\/2326409818759370","article-title":"Outcomes of a physician survey on the type, progression, assessment, and treatment of neurological disease in mucopolysaccharidoses","volume":"6","author":"Scarpa","year":"2018","journal-title":"J. Inborn Errors Metabol. Screen."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0955","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10545-011-9430-5","article-title":"Intellectual and neurological functioning in Morquio syndrome (MPS IVa)","volume":"36","author":"Davison","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0960","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","article-title":"The Morquio A clinical assessment program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects","volume":"109","author":"Harmatz","year":"2013","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0965","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-9-32","article-title":"Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey","volume":"9","author":"Hendriksz","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0970","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-9-32","article-title":"Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey","volume":"9","author":"Hendriksz","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0975","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10545-014-9737-0","article-title":"Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey","volume":"38","author":"Brands","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb0980","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ymgme.2018.02.002","article-title":"Neurophysiology of hearing in patients with mucopolysaccharidosis type IV","volume":"123","author":"Nagao","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb0985","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ymgme.2016.04.005","article-title":"Activity of daily living for Morquio A syndrome","volume":"118","author":"Yasuda","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb0990","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-017-0633-1","article-title":"Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome","volume":"12","author":"Schrover","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2021.03.002_bb0995","first-page":"31","article-title":"Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA","volume":"1","author":"Chinen","year":"2014","journal-title":"Mol. Genet. Metabol. Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb1000","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymgme.2015.09.011","article-title":"Hematopoietic stem cell transplantation for Morquio A syndrome","volume":"117","author":"Yabe","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2021.03.002_bb1005","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/ajmg.a.36424","article-title":"Mucopolysaccharidosis type IVA: evidence of primary and secondary central nervous system involvement","volume":"164","author":"Borlot","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"issue":"3-4","key":"10.1016\/j.ymgme.2021.03.002_bb1010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/02643294.2018.1443913","article-title":"Markers of cognitive function in individuals with metabolic disease: Morquio syndrome and tyrosinemia type III","volume":"35","author":"Blundell","year":"2018","journal-title":"Cogn. Neuropsychol."},{"key":"10.1016\/j.ymgme.2021.03.002_bb1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2018.12.353","article-title":"Evidence of attention problems in Morquio syndrome","volume":"126","author":"Spurlock","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.03.002_bb1020","series-title":"JIMD Reports","first-page":"87","article-title":"Psychological health in adults with morquio syndrome","volume":"vol. 20","author":"Ali","year":"2014"},{"key":"10.1016\/j.ymgme.2021.03.002_bb1025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2741\/4490","article-title":"Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment","volume":"22","author":"Harmatz","year":"2017","journal-title":"Front. Biosci. (Landmark Ed)"},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb1030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2478\/s11536-010-0072-z","article-title":"Natural history of Polish patients with mucopolysaccharidosis type VI","volume":"6","author":"Jurecka","year":"2011","journal-title":"Open Med."},{"issue":"12","key":"10.1016\/j.ymgme.2021.03.002_bb1035","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/humu.23613","article-title":"Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene","volume":"39","author":"Tomanin","year":"2018","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2021.03.002_bb1040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-1172-5-5","article-title":"Mucopolysaccharidosis VI","volume":"5","author":"Valayannopoulos","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2021.03.002_bb1045","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/ajmg.a.36489","article-title":"Clinical manifestations of 17 patients affected with mucopolysaccharidosis type VI and eight novel ARSB mutations","volume":"164a","author":"Kantaputra","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb1050","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1399-0004.2004.00277.x","article-title":"Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI","volume":"66","author":"Azevedo","year":"2004","journal-title":"Clin. Genet."},{"issue":"9","key":"10.1016\/j.ymgme.2021.03.002_bb1055","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/humu.20534","article-title":"Mutational analysis of 105 mucopolysaccharidosis type VI patients","volume":"28","author":"Karageorgos","year":"2007","journal-title":"Hum. Mutat."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb1060","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.a.30579","article-title":"Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"134a","author":"Swiedler","year":"2005","journal-title":"Am. J. Med. Genet. A"},{"issue":"8","key":"10.1016\/j.ymgme.2021.03.002_bb1065","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/ajmg.a.36584","article-title":"Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study","volume":"164a","author":"Giugliani","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb1070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12687-017-0329-1","article-title":"The clinical and genetic Spectrum of Maroteaux-Lamy syndrome (Mucopolysaccharidosis VI) in the Eastern Province of Saudi Arabia","volume":"9","author":"Al-Sannaa","year":"2018","journal-title":"J. Community Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb1075","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10545-015-9895-8","article-title":"Long-term cognitive follow-up in children treated for Maroteaux-Lamy syndrome","volume":"39","author":"Ebbink","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"issue":"7","key":"10.1016\/j.ymgme.2021.03.002_bb1080","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.braindev.2013.07.016","article-title":"New insights in mucopolysaccharidosis type VI: neurological perspective","volume":"36","author":"Borlot","year":"2014","journal-title":"Brain and Development"},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb1085","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10545-012-9559-x","article-title":"Brain magnetic resonance imaging findings in patients with mucopolysaccharidosis VI","volume":"36","author":"Azevedo","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"issue":"7","key":"10.1016\/j.ymgme.2021.03.002_bb1090","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.nrl.2011.10.007","article-title":"Neuroimaging findings in patient series with mucopolysaccharidosis","volume":"27","author":"Calleja Gero","year":"2012","journal-title":"Neurologia"},{"issue":"10","key":"10.1016\/j.ymgme.2021.03.002_bb1095","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00247-018-4139-3","article-title":"Mucopolysaccharidoses: overview of neuroimaging manifestations","volume":"48","author":"Nicolas-Jilwan","year":"2018","journal-title":"Pediatr. Radiol."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb1100","first-page":"83","article-title":"N\u00edvel de independ\u00eancia, capacidade funcional e for\u00e7a muscular respirat\u00f3ria de pacientes com mucopolissacaridose tipo VI no Nordeste do Brasil","volume":"18","author":"Figueir\u00eado","year":"2018","journal-title":"Rev. Bras. Sa\u00fade Mat. Inf."},{"issue":"25","key":"10.1016\/j.ymgme.2021.03.002_bb1105","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJM198412203112504","article-title":"Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation","volume":"311","author":"Krivit","year":"1984","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb1110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ymgme.2010.09.010","article-title":"Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI","volume":"102","author":"Turbeville","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb1115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1023\/A:1005447232027","article-title":"Bone marrow transplantation for Maroteaux\u2013Lamy syndrome (MPS VI): long-term follow-up","volume":"22","author":"Herskhovitz","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb1120","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12519-008-0031-9","article-title":"Long-term follow-up of a girl with Maroteaux-Lamy syndrome after bone marrow transplantation","volume":"4","author":"Wang","year":"2008","journal-title":"World J. Pediatr."},{"issue":"108","key":"10.1016\/j.ymgme.2021.03.002_bb1125","first-page":"S17","article-title":"Medical and treatment status correlates with central nervous system outcomes in mucopolysaccharidosis type VI","volume":"2","author":"Ahmed","year":"2013","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb1130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10545-011-9410-9","article-title":"Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP)","volume":"36","author":"Hendriksz","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb1135","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"Harmatz","year":"2006","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb1140","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.ymgme.2019.11.335","article-title":"Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): Symptoms and the impact on function and activities of daily living (ADL)","volume":"129","author":"Phillips","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.03.002_bb1145","series-title":"Molecular Genetics and Metabolism","article-title":"The MPS VII disease monitoring program (DMP) is a novel, longitudinal, cohort program with rigor beyond a traditional registry","author":"Marsden","year":"2019"},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb1150","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ymgme.2018.02.006","article-title":"A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease","volume":"123","author":"Harmatz","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb1155","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0022-3476(73)80162-3","article-title":"Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis","volume":"82","author":"Sly","year":"1973","journal-title":"J. Pediatr."},{"issue":"4","key":"10.1016\/j.ymgme.2021.03.002_bb1160","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/humu.20828","article-title":"Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly Syndrome)","volume":"30","author":"Tomatsu","year":"2009","journal-title":"Hum. Mutat."},{"issue":"6","key":"10.1016\/j.ymgme.2021.03.002_bb1165","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jmedgenet-2015-103322","article-title":"Clinical course of sly syndrome (mucopolysaccharidosis type VII)","volume":"53","author":"Monta\u00f1o","year":"2016","journal-title":"J. Med. Genet."},{"issue":"9","key":"10.1016\/j.ymgme.2021.03.002_bb1170","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/gim.2017.10","article-title":"Quantitative clinical characteristics of 53 patients with MPS VII: a cross-sectional analysis","volume":"19","author":"Zielonka","year":"2017","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb1175","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13023-019-1233-z","article-title":"Pathway to diagnosis and burden of illness in mucopolysaccharidosis type VII - a European caregiver survey","volume":"14","author":"Morrison","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb1180","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1034\/j.1399-0004.2003.00119.x","article-title":"Mucopolysaccharidosis VII: clinical, biochemical and molecular investigation of a Brazilian family","volume":"64","author":"Schwartz","year":"2003","journal-title":"Clin. Genet."},{"issue":"6","key":"10.1016\/j.ymgme.2021.03.002_bb1185","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bmt.1701141","article-title":"Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation","volume":"21","author":"Yamada","year":"1998","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb1190","article-title":"Long-term follow-up posthematopoietic stem cell transplantation in a japanese patient with type-VII mucopolysaccharidosis","volume":"10","author":"Orii","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"10.1016\/j.ymgme.2021.03.002_bb1195","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13278","article-title":"Haematopoietic stem cell transplantation for mucopolysaccharidosis type VII: A case report","volume":"22","author":"Sisinni","year":"2018","journal-title":"Pediatr. Transplant."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb1200","first-page":"155","article-title":"A new case report of severe mucopolysaccharidosis type VII: diagnosis, treatment with haematopoietic cell transplantation and prenatal diagnosis in a second pregnancy","volume":"44","author":"Furlan","year":"2018","journal-title":"Ital. J. Pediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb1205","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ymgme.2020.02.009","article-title":"Vestronidase alfa: recombinant human \u03b2-glucuronidase as an enzyme replacement therapy for MPS VII","volume":"130","author":"Cadaoas","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb1210","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ymgme.2014.10.017","article-title":"First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient","volume":"114","author":"Fox","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2021.03.002_bb1215","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2020.01.003","article-title":"The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII","volume":"129","author":"Wang","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2021.03.002_bb1220","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40262-018-0721-y","article-title":"Pharmacokinetic and pharmacodynamic modeling to optimize the dose of vestronidase alfa, an enzyme replacement therapy for treatment of patients with mucopolysaccharidosis type VII: results from three trials","volume":"58","author":"Qi","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.002_bb1225","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40259-019-00344-7","article-title":"Vestronidase alfa: a review in mucopolysaccharidosis VII","volume":"33","author":"McCafferty","year":"2019","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.ymgme.2021.03.002_bb1230","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41436-019-0616-9","article-title":"Developing interactions with industry in rare diseases: lessons learned and continuing challenges","volume":"22","author":"Berry","year":"2020","journal-title":"Genet. Med."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221000585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221000585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:30:04Z","timestamp":1761089404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719221000585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":246,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1096719221000585"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.03.002","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The natural history of neurocognition in MPS disorders: A review","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}